Emerging Therapies in Hypercortisolism

In ‘Emerging Therapies in Hypercortisolism,’ our panel explores the evolving therapeutic landscape for hypercortisolism and the future direction of treatment development. The panelists emphasize that while diagnostic approaches have been simplified, particularly using the dexamethasone suppression test, therapeutic strategies must also become more practical and accessible to enable broader adoption across specialties, including cardiology.

The discussion highlights several emerging treatment approaches, including adrenal-directed therapies, more selective glucocorticoid receptor modulators, and enzyme-targeting strategies aimed at reducing cortisol production. Expert faculty note that improving specificity and minimizing off-target effects will be critical to enhancing tolerability and usability in clinical practice. At the same time, they underscore physiological challenges associated with treatment, such as patient adaptation to chronically elevated cortisol levels, which may complicate normalization efforts.

Importantly, the panelists draw parallels to other conditions once considered rare, such as amyloidosis and pulmonary hypertension, where advances in therapeutics drove increased awareness, screening, and diagnosis. A similar shift may occur in hypercortisolism as new therapies emerge. However, the expert faculty emphasizes the need for robust clinical trials, including cardiovascular outcomes data, to support broader adoption. Overall, the discussion reflects cautious optimism that innovation in therapeutics will expand both recognition and management of hypercortisolism.

Our next episode, ‘Risk-Based Management in Hypercortisolism,’ the expert faculty discuss managing hypercortisolism as a cardiovascular risk factor in the absence of targeted therapies. The focus is on aggressive risk factor control and routine screening in high-risk patients.